Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Banyan Biomarkers, a developer of in vitro diagnostic products for the detection of traumatic brain injury, has received a new patent from the US Patent and Trademark Office. This patent was licensed exclusively by Banyan Biomarkers from the University of Florida with the company as co-inventor.
Subscribe to our email newsletter
This newly issued patent describes a method of determining the presence of neural injury through the measurement of proteolytic breakdown products of microtubule-associated proteins (MAP).
The company has developed enzyme linked immunosorbent assays that detect MAP and is conducting a clinical study designed to evaluate MAP as an indicator of traumatic brain injury (TBI). The company’s goal is to seek FDA regulatory review for the use of MAP as an aid in the detection and monitoring of TBI.
Gary Ascani, CEO of Banyan Biomarkers, said: “We are very pleased with the addition of this patent to Banyan’s intellectual property portfolio of TBI biomarkers. With nearly two million people experiencing TBI annually in the US and no available point-of-care diagnostic test, Banyan is paving the way in establishing the leadership position in the discovery, validation and development of products for the detection of traumatic brain injury.”